Form 8-A12B Logicbio Therapeutics, Inc.

Registration of securities [Section 12(b)]

Published: 2018-10-17 16:46:18
Submitted: 2018-10-17
d638592d8a12b.htm 8-A12B


> ENT> 8-A12B 1 d638592d8a12b.htm 8-A12B

8-A12B

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 


FORM 8-A

 

 


For Registration of Certain Classes of Securities

Pursuant to Section 12(b) or (g) of

the Securities Exchange Act of 1934

 

 


LOGICBIO THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

 


 

Delaware   47-1514975
(State or other jurisdiction of incorporation or organization)   (I.R.S. Employer Identification No.)

610 Main Street, 3rd Floor

Cambridge, Massachusetts

United States

  02139
(Address of principal executive offices)   (Zip Code)

Securities to be registered pursuant to Section 12(b) of the Act:

 

Title of each class

to be so registered

 

Name of each exchange on which

each class is to be registered

Common Stock, $0.0001 par value   The Nasdaq Stock Market LLC

 

 


If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c) or (e), check the following box.  ☒

If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d) or (e), check the following box.  ☐

If this form relates to the registration of a class of securities concurrently with a Regulation A offering, check the following box.  ☐

Securities Act registration statement or Regulation A offering statement file number to which this form relates (if applicable):

333-227523

Securities to be registered pursuant to Section 12(g) of the Act:

None

 

 

 



Item 1. Description of Registrant’s Securities to be Registered.

LogicBio Therapeutics, Inc. (the “Registrant”) hereby incorporates by reference the description of its common stock, $0.0001 par value per share, to be registered hereunder, contained under the heading “Description of Capital Stock” in the Registrant’s Registration Statement on Form S-1 (File No. 333-227523) (the “Registration Statement”) filed with the Securities and Exchange Commission (the “Commission”) under the Securities Act of 1933, as amended (the “Act”). Any form of prospectus subsequently filed by the Registrant with the Commission pursuant to Rule 424(b) under the Act that constitutes part of the Registration Statement shall also be deemed to be incorporated herein by reference.

Item 2. Exhibits.

Pursuant to the Instructions as to Exhibits, no exhibits are filed herewith or incorporated herein by reference.

 

2



SIGNATURE

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the Registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereto duly authorized.

 

Date: October 17, 2018     LOGICBIO THERAPEUTICS, INC.
    By:   /s/ Frederic Chereau
    Name:   Frederic Chereau
    Title:   President and Chief Executive Officer

 

3


Additional Files
FileSequenceDescriptionTypeSize
0001193125-18-301114.txt   Complete submission text file   13835

© 2019 SEC.report
SEC CFR Title 17 of the Code of Federal Regulations.